We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Mycelx Technologies Corporation | MYX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 56.00 | 15:18:53 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 56.00 | 56.00 | 56.50 | 56.00 | 56.00 |
| Industry Sector |
|---|
| OIL EQUIPMENT SERVICES & DISTRIBUTION |
| Top Posts |
|---|
Posted at 27/2/2024 12:30 by slicethepie They seem totally unaware of how to promote their company, they use / pay a broker that doesn't distribute its research to private investors. The natural investors in a company of this size are hnw yet they do not attend events such as mello! Like you I wonder if Connie is the problem. |
Posted at 22/2/2024 08:06 by hornets89 The financing issue was clearly a huge worry here, so with the asset sale maybe some breathing room gives investors a bit of confidence. Long way to go still but an interesting company |
Posted at 30/1/2024 18:45 by fft I agree. I think they are spread too thinly given the markets they are in. A strategic investor like SLB would be huge (though I suspect a complete takeover would be more likely).I would be happy for them, for example, to give up the oil side in order to throw more resources at the PFAS side - which is multi billion and worldwide. A small number of contracts have been awarded in the last few the USA for this, but so far MYX arent winning them. But the USA EPA site shows hundreds if not 1000's of contracts that will come up. It just takes a few years to process them. There has been a year end TU in recent years. But this has been in January, February or March (!) so impossible to predict. |
Posted at 24/1/2024 16:24 by kinbasket I would imagine investors (what few investors there are left in small cap UK) are concerned about cash. They had $1.4m at the half year in June 23. Things must be a bit tight and a fundraise seems inevitable.It's what's keeping me on the sidelines at the moment despite the obvious regulatory tailwind for their technology. |
Posted at 24/1/2024 14:39 by slicethepie They announced one 6 weeks ago ! Clearly they need to tell their story more widely to potential investors. Most investors would not believe the opportunity they are sitting on and the legislative wind that is blowing in their favour. Their patent portfolio is very impressive and researching into this area would show little competition.All imo dyor |
Posted at 20/10/2023 12:35 by slicethepie Our misleading poster has clearly scared a few investors ! |
Posted at 06/7/2023 09:04 by slicethepie Biggest Investor mopping up inpatient holders bodes well! |
Posted at 08/12/2022 08:07 by slicethepie Fwiw share price has fallen 50% in the last 4 weeks which perhaps suggests some investors need reassurance! |
Posted at 11/2/2022 13:51 by concentrate Revenue of the following:2020H1 - $3.6m 2020H2 - $3.9m 2021H1 - $4.2m 2021H2 - $4.3m Current cash burn of $1.3m per half year. A Gross Margin of just shy of 50%, so another $6m of annual revenue needed before cash break even (all else being equal). Overall I thought it was an honest but poorly worded RNS. "targeting a similar level of year-on-year revenue growth but this remains subject to the timing of anticipated contract wins and renewals" The sentence sounds so negative, "but" this remains subject to.. "similar levels"... I imagine given the revenue levels, any single deal could materially impact these numbers either way. The sentence even seems to cast doubt on new projects materialising over the year. They could have written something like "targeting strong year-on-year growth to continue based on our current anticipated contract wins and renewals, although the precise timing of these is not known." I really agree that the oil recovery bodes well for the core business, and hope they can capitalise on that. I agree with someuwin, most investors are following the PFAS. I said earlier than I'm most interested in hearing how the financials for this use case are currently arranged. (e.g. contract size, market size, gross margin, etc.). |
Posted at 27/1/2022 16:29 by concentrate Agreed, I watched this and it's interesting.My concern is simply financial. I've been convinced that the potential market is huge and that Mycelx has a leading technology that could get widespread adoption. But what revenue share do they get when they partner with Oleology? To illustrate with imaginary numbers: if Oleology win a $1m contract for PFAS remediation, with a gross margin of $500k, do Mycelx receive $2k? $25k? $250k, $400k? The whole of the Oleology website is centred around Mycelx tech. Their clients are huge corporations. They talk about widespread adoption in Australia. But Mycelx have <$10m in revenue and they are not required to report Oleology as a material customer, leading me to conclude that their revenue from Oleology is currently immaterial to the business. Possibly they each bill end customers separately, but this seems unnecessarily complex. Or Mycelx sell the filters separately, which seems to cut us out of the lucrative parts of the contract. As Olelogy are now trialling in the US, I'm just hoping the opportunity will work for our benefit also. Hope that's clear. I will probably ask the question at the next investor presentation. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
